Summary Vitamin A has been shown to potentiate the cytotoxic action of anticancer agents like vincristine (VCR) against drug resistant mouse P388 leukaemia cells. In vitro tests showed enhancement by retinyl acetate of cytocidal activities of VCR against drug-sensitive leukaemia (P388/S) and VCR-resistant leukaemia (P388/VCR) cells in culture; retinyl acetate rather specifically potentiated VCR against cultured P388/VCR cells than P388/S cells. The cellular aceumulation of radioactive VCR was significantly enhanced in cultured P388/VCR cells when retinyl acetate was present. The efflux of VCR from drug-resistant cells was blocked by retinyl acetate. The effect of the combination of vitamin A and VCR was also tested in vivo on the life-span of mice bearing P388/S or P388/VCR. Intraperitoneal administration of retinyl palmitate at 41.75 or 83.5 mg kg-was effective to potentiate the antileukaemic activity of VCR against P388/S bearing mice, and it also overcame vincristine-resistance in P388/VCR bearing mice.
The development of resistance to anticancer agents is often a serious clinical problem in the treatment of cancer patients. The development of a methodology to overcome drugresistance would be invaluable . Drug resistance is circumvented in cultured mammalian tumour cells in vitro by various membrane active agents such as verapamil (Fojo et al., 1985; Rogan et al., 1984; Tsuruo et al., 1981) , lysosomotropic amines , isoprenoids phenothiazine calmodulin inhibitors ) and a biscolaurine alkaloid, cepharanthine (Shiraishi et al., 1987) . In vivo studies with animals carrying drug-resistant tumours have shown that verapamil (Tsuruo et al., 1981) or isoprenoids are also effective. To apply such combination therapy clinically, the agents which overcome drug resistance should be nontoxic. As a plausible compound to combine, we used vitamin A which is a membrane active agent. Combination of vitamin A and anticancer agents has exhibited synergistic antitumour effects on various tumours in vivo (Akiyama et al., 1981; Cohen & Carbonne, 1972; Nakagawa et al., 1985; Tomita et al., 1982) . In this report, the effect of vitamin A on drug resistance in leukaemia cells is studied; some ability of vitamin A to overcome drug resistance is observed.
Materials and methods
Cell line and cell culture P388/S, and its resistant subline P388/VCR, were obtained from Dr M. Inaba (Cancer Chemotherapy Cancer, Japanese Foundation for Cancer Research, Tokyo, Japan). This resistant subline was developed by in vivo treatment of drugsensitive P388 leukaemia cells (P388/S) with VCR (Inaba et al., 1979) . Both sublines were passaged weekly by i.p. inoculation in BALB/c x DBA/2 (CDFl) mice (Shizuoka Agricultural Cooperative Association for Laboratory Animals, Hamamatsu, Japan) without drug injection. The relative resistance of each cell line to anticancer agents was confirmed for each assay because the phenotype of resistance is relatively unstable under in vitro conditions. Cells from P388/S or its resistant sublines were suspended in RPMImedium (Grand Island In vivo antitumour activity P388/VCR was inoculated at 106 cells per mouse i.p. into male CDF1 mice. These mice were 5 to 6 weeks of age and weighed 18 to 22 g. Groups of 6 mice were housed in plastic cages and were given pelleted food and water ad libitum as described previously . RP was injected i.p. daily from day 1 to 8. VCR dissolved in sterile pysiological saline was also administered simultaneously. The experiment was terminated on day 30. The therapeutic response was measured as the mean day of death of 6 mice group as described previously (Nakagawa et al., 1985; Yamaguchi et al., 1986 1 ; NaCl, 8,0; Na2HPO4. 12H20, 2.9; KCl, 0.2; KH2PO4, 0.2) was added to each well at 4°C. The cell pellets were harvested by centrifugation and washed three times with PBS, suspended in 0.9 ml of H20 and 10 ml of Scintisol EX-H (Wako Chemical Co., Osaka, Japan), and their radioactivity was then measured with ice-cold PBS at 4°C and efflux was followed over 120 min at 37°C in serum-free and radioisotope-free medium with or without RA. At the time indicated, cells were harvested and their radioactivity was determined .
Drug influx assay
Cells growing exponentially at a density of 5 x 105 per well and control plates were incubated in glucose-free and serumfree HANKS balanced salt solution (HBSS) and exposed to various doses of RA for 3 h. The cells were further incubated with 1 mM 2,4-dinitrophenol for 10 min to inhibit drug efflux and followed by exposure to 26 nM [3H] VCR for 1 min at 37°C Shiraishi et al., 1987) . The cells were then harvested by centrifugation and the radioactivity associated with them determined.
Differences in drug sensitivity to VCR was observed between P388/S and P388/VCR: P388/S cell growth was inhibited 50% by 50 ng VCR ml-1, whereas growth of P388/VCR was inhibited by 50% at 2,000 ng VCR ml-1 (Figure la) . P388/VCR thus shows 20-to 40-fold greater resistance to VCR than the sensitive P388/S. Cellular sensitivity to RA was found to be similar between P388/S and P388/VCR: the surviving fraction of both P388/S and P388/VCR was decreased by only 10% of the initial fraction when 20 ,ug RA ml-1 was present. Figure 1 also shows that RA partially overcomes VCR resistance in P388/VCR. The sensitivity of P388/VCR to VCR was enhanced 2-to 4-fold higher when 10 or 20 jigml-1 RA was present. By contrast, the cellular sensitivity of P388/S to VCR was not significantly enhanced by RA (Figure la) . Some partial effect of RA on the circumvention of VCR resistance in mouse leukaemia cells was observed. Serum contains vitamin A binding proteins like retinol binding protein or other related proteins (Goodman, 1984) , and serum might therefore interfere with the circumventing effect of RA against the leukaemia cells. We thus treated the cells with VCR or/and RA for 3 h under serum-free conditions, and then constructed the growth curves. As seen in Figure lb , the circumventing effect of RA against P388/VCR was magnified. The IC50 for P388/VCR was 2,000, 600 and 800 ng VCR ml-1 in the presence of 0, 10 and 20 jug RA ml-1, indicating that RA enhanced the cellular sensitivity of the resistant cells from 8-to 25-fold. The cellular sensitivity of P388/S to VCR was slightly (2-to 3- Effect of combination of vitamin A on VCR resistance of mouse leukaemia cells in culture P388/VCR is established by repeated administration of VCR to P388/S leukaemia bearing mice (Inaba & Johnson, 1978) . To determine drug effects in the in vitro assay with P388/VCR or P388/S cells, we measured cell survival by constructing cell growth curves and clonogenic assay. We first treated P388/S or P388/VCR cells in the presence of VCR or/and RA for 3 h in medium with or without 10% serum, washed with drug-free fresh medium and followed incubation in 10% serum-supplemented medium in the absence of any drug. The cellular sensitivity to drugs of P388/VCR was compared with that of the parental P388/S by assaying the growth inhibition in vitro at 4th day after the treatment. We examined the effect of VCR alone or with RA on growth of P388/S and P388/VCR when treatment for 3 h with drugs was performed in the presence of serum. Exponentially growing P388/S (0, A, El) and P388/VCR (0, *, *) cells were seeded either in 10% serum-supplemented medium (a) or in serum-free medium (b), and the cells were exposed to various doses of VCR in the absence (0, 0) or in the presence of 10 gml -(A, A) and 20pgml 1 (E1, *) of RA for 3h. The cells were then followed by incubation for a further 4 days in a drug-free and fresh serum-supplemented medium. Each value is the average of duplicate dishes. Although RA alone at 10 or 20 ygml-' had a slight effect on the growth of P388/VCR (Figure 2a ), combination with VCR showed a dramatic reduction in the growth rate ( Figure 2b ). We also tested the effect of RA on drug resistance in P388/VCR leukaemia cells by clonogenic assay in soft agar. Since colony forming ability of P388/VCR was found to be about 1/5 of that of P388/S, we plated a 5-fold greater number of P388/VCR cells than P388/S cells into each dish. As seen in Table I , the surviving fraction of P388/VCR synergistically decreased when combined with 10 pg ml-1 RA. RA enhanced the cellular sensitivity of P388/VCR to VCR more than 4-fold when 10 or 40 ng ml-1 VCR was present (Table I) . RA alone at 10 pg ml-1 only slightly affected the cell survival of P388/VCR as well as P388/S. RA also enhanced the cellular sensitivity to VCR of P388/S cell when 1 ng ml-1 of VCR and RA were combined. Both assays for measuring cell survival by cell growth and colony form- (Inaba & Johnson, 1978; Inaba et al., 1979) . We determined whether increased accumulation of anticancer agents in the resistant leukaemia cells by vitamin A is due to altered efflux and/or influx. To test the effect of vitamin A on drug efflux activity, the cells were exposed to [3H] VCR for 60min, followed by incubation with or without 50 pg RAml-1 in medium containing no isotope (Figure 4 ). More than 50% of cell associated radioactive VCR in P388/VCR cells was released into medium after 30 min of incubation in the absence of RA, and then there was a slight subsequent release of the radioactivity at 37°C. In contrast, in the parental cells, the release of VCR into medium proceeded much more slowly, and > 50% of the initial activity still remained after 90min incubation ( Figure  4 ). Efflux of VCR from P388/VCR was significantly blocked by 50,ug RA ml-': more than 60% of the initial activity remained in RA-treated P388/VCR cells even after 120min incubation (Figure 4 ). In the sensitive P388/S cells, treatment with RA did not significantly interfere with drug efflux. The effect of RA on cellular uptake (influx) of VCR was also examined (Figure 5 ). Treatment of P388/VCR with 2,4-dinitrophenol increased accumulation of VCR only slightly if at all (c.f. Figures 3 and 5) . As a function of dose of RA, accumulation of VCR into P388/VCR and P388/S increased about 2-fold ( Figure 5 ).
Effect of vitamin A on antitumour activity of VCR in P388/S-and P388/ VCR-bearing mice We tested the in vivo effect of vitamin A to potentiate VCR against drug-resistant leukaemia bearing mice. Since RA is toxic and unstable in vivo, we used RP for in vivo tests. Our previous study showed that RP at 167 mg kg-produced synergistic antitumour activity of various anticancer agents against P388/S bearing mice (Nakagawa et al., 1985) . We used various doses of RP ranging from 41.75-83.5 mgkg-'.
These doses of RP alone were found to be nontoxic in mice. We first tested the in vivo effect of RP and VCR on VCRresistant P388/VCR bearing mice. VCR at 5, 10 and 30,ugkg-administered daily for 8 days starting from day 1 increased the life-span of P388/S bearing mice significantly, up to 2-fold (Table II) .
We then tested the effect of RP and VCR treatment on P388/VCR bearing mice. RP alone at 41.75-83.5 mgkggave no therapeutic effect (Table II) . To obtain similar therapeutic effects on P388/VCR bearing mice as on P388/S bearing mice by VCR alone, 3-fold to 6-fold higher doses of VCR were required. The combination of VCR with RP synergistically increased the life-span in all combination trials Retinyl acetate (p,g ml -1) Figure 5 Effect of RA on drug influx. P388/S (Li]) and P388/VCR (3) pre-exposed to various doses of RA were further incubated with 1 mM 2,4-dinitrophenol, and then exposed to
[3H] VCR. The values are mean +s.d. from triplicate dishes. of two different doses of VCR with RP by up to 36% (Table   II) . (Dan0, 1978; Inaba & Johnson, 1978; Skovsgaard, 1978) . Decreased drug permeability has been considered to be involved in drug resistance (Biedler & Riehm, 1970; Inaba et al., 1979; Siegfried et al., 1985) . Although it has remained unclear how the transport system is deranged in drugresistant tumour cells, recent study suggests increased binding of vinblastine and its analogs to the high molecular weight surface membrane P-glycoprotein specific for multidrug resistant tumour cells (Cornwell et al., 1986; Sofa et al., 1986) . Verapamil, a potent agent in the circumvention of multidrug resistance, inhibits the binding of vinblastine to the membrane protein (Cornwell et al., 1986) . It would be interesting to determine whether RA interacts with the specific glycoprotein implicated in multidrug resistance.
The effect of vitamin A on plasma membranes was earlier shown to involve decreased stability of the membrane phospholipid (Lucy, 1970; Lucy & Dingle, 1964) . Alteration of membrane lipids might secondarily change the membrane transport system. In this study, RA inhibited efflux of VCR from P388/VCR cells, resulting in enhanced accumulation of VCR. Since efflux is enhanced in drug-resistant tumour cells, any agent which inhibits drug efflux might overcome drug resistance . Vitamin A like RA overcomes drug resistance possibly through inhibition of drug efflux from P388/VCR cells. However, the drug efflux from drug-sensitive P388/S cells is not enhanced. The stimulatory effect of vitamin A on VCR accumulation in P388/S cells appears to be caused by enhanced uptake activity of the anticancer agent rather than its inhibitory effect on drug efflux. RP-induced potentiation in vivo of VCR against P388/S leukaemia bearing mice might be partly due to its stimulatory effect on the drug uptake activity. On the other hand, vitamin A and its analogues are powerful immunological adjuvants (Dressler, 1980; Glaser & Lotan, 1979; Tannock et al., 1972) . This immunoadjuvant activity of vitamin A might also have some influence on the vitamin A effect in vivo against P388/S as well as P388/VCR leukaemia bearing mice.
Our recent relevant study has shown that synthetic isoprenoids with 9-to 10-isoprene chains potentiate various anticancer agents Yamaguchi et al., 1984) and some of them overcome drug resistance to anticancer agents in vivo as well as in vitro Yamaguchi et al., 1986) . The combination of anticancer agents with these isoprenoids is thus expected to be useful not only in overcoming drug resistance but also in the enhancement of the antitumour activities of anticancer agents. Concerning vitamin A or other retinoids, the combination of retinol type vitamin A with anticancer agents causes synergistic antitumour effects against various tumour cell systems (Akiyama et al., 1981; Cohen & Carbone, 1972; Nakagawa et al., 1985; Tomita et al., 1982) . On the other hand, blood levels of vitamin A including retinol have been shown to be decreased in patients with various cancers as compared to control groups (Atukorala et al., 1986; Ibrahim et al., 1977) . Cancer patients with higher levels of serum retinol respond more favourably to chemotherapy than those with lower levels of retinol (Soukop & Calman, 1978) . These reports suggest a close correlation between plasma retinol levels and efficacy of cancer chemotherapy. Anticancer combination therapy with vitamin A might be expected to produce improved antitumour effects against drug-sensitive and drug-resistant populations of cancer cells. Clinical trials of the vitamin A therapy will be necessary to verify the above prediction.
